Omsana AM (olmesartan medoxomil + amlodipine): Uses, Dosage & Side Effects

What it's for (Indications)

Olmesartan medoxomil and amlodipine combination therapy is indicated for the treatment of hypertension in adult patients.
This fixed-dose combination is typically prescribed when monotherapy with either olmesartan or amlodipine alone is insufficient to achieve desired blood pressure control, or as a convenient alternative for patients already maintained on separate components.
By addressing distinct pathways involved in blood pressure regulation, this combination offers a synergistic approach to lowering elevated blood pressure, thereby reducing the risk of cardiovascular morbidity and mortality associated with uncontrolled hypertension.
The efficacy has been demonstrated in various clinical trials, showing superior blood pressure reduction compared to monotherapy.
It aims to achieve target blood pressure goals, which are crucial for long-term cardiovascular health management.

Dosage Information

Type	Guideline
Standard	The dosage of olmesartan medoxomil and amlodipine combination therapy must be individualized based on the patient's existing blood pressure control, tolerance to each component, and overall clinical response. It is typically administered orally once daily. Initial dosing should consider whether the patient is new to antihypertensive therapy or transitioning from monotherapy. Common starting strengths include combinations such as olmesartan 20 mg/amlodipine 5 mg. Dose adjustments should be made gradually, typically at intervals of at least two weeks, to allow for full pharmacological effect and to assess efficacy and tolerability. The maximum recommended daily dose for olmesartan is 40 mg and for amlodipine is 10 mg. Specific dose adjustments may be necessary for patients with renal impairment or moderate hepatic impairment; however, severe hepatic impairment may contraindicate its use or necessitate significant dose reduction and careful monitoring. Regular monitoring of blood pressure is essential to guide appropriate dosage titration and ensure optimal therapeutic outcomes while minimizing adverse effects.

Type

Guideline

Standard

The dosage of olmesartan medoxomil and amlodipine combination therapy must be individualized based on the patient's existing blood pressure control, tolerance to each component, and overall clinical response. It is typically administered orally once daily. Initial dosing should consider whether the patient is new to antihypertensive therapy or transitioning from monotherapy. Common starting strengths include combinations such as olmesartan 20 mg/amlodipine 5 mg. Dose adjustments should be made gradually, typically at intervals of at least two weeks, to allow for full pharmacological effect and to assess efficacy and tolerability. The maximum recommended daily dose for olmesartan is 40 mg and for amlodipine is 10 mg. Specific dose adjustments may be necessary for patients with renal impairment or moderate hepatic impairment; however, severe hepatic impairment may contraindicate its use or necessitate significant dose reduction and careful monitoring. Regular monitoring of blood pressure is essential to guide appropriate dosage titration and ensure optimal therapeutic outcomes while minimizing adverse effects.

Safety & Warnings

Common Side Effects

Patients receiving olmesartan medoxomil and amlodipine may experience a range of side effects, generally reflecting the profiles of the individual components.
Common adverse reactions include peripheral edema (primarily attributable to amlodipine), headache, dizziness, fatigue, nasopharyngitis, and upper respiratory tract infections.
Gastrointestinal disturbances such as nausea or abdominal pain, and musculoskeletal pain, are also reported.
More serious, albeit less common, adverse events warrant immediate medical attention.
These include significant hypotension, particularly in volume-depleted individuals, and hyperkalemia, especially in patients with renal impairment, those on potassium-sparing diuretics, or potassium supplements due to the olmesartan component.
Renal dysfunction or worsening of existing renal impairment can occur.
Rarely, angioedema has been reported with ARBs like olmesartan, manifesting as swelling of the face, lips, tongue, and/or larynx.
Severe skin reactions, hepatic enzyme elevations, and jaundice are also possible.
Patients should be counseled on recognizing signs of serious adverse effects and advised to seek medical help promptly if they occur.
Regular monitoring of renal function and electrolytes is prudent during therapy.

Serious Warnings

Black Box Warning: WARNING: FETAL TOXICITY. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, discontinue olmesartan medoxomil + amlodipine as soon as possible. Although there is no experience with the use of olmesartan medoxomil + amlodipine in pregnant women, exposure to angiotensin receptor blockers (ARBs) during the second and third trimesters of pregnancy is known to cause fetal injury and death. Such injuries include oligohydramnios, which can result in fetal lung hypoplasia and skeletal deformities, and neonatal anuria, hypotension, and death. If olmesartan medoxomil + amlodipine is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing age should be counseled on the potential risks of olmesartan exposure during pregnancy and advised to use effective contraception if appropriate, or to seek alternative treatments if planning pregnancy. Discontinuation of this medication is imperative upon confirmation of pregnancy to mitigate these severe risks.
Several critical warnings are associated with the use of olmesartan medoxomil and amlodipine.
Symptomatic hypotension, especially in patients with activated renin-angiotensin system, such as those who are volume- and/or salt-depleted (e.
g.
, those on high-dose diuretics), may occur.
This requires correction of volume depletion prior to therapy initiation or or close medical supervision.
The olmesartan component carries a risk of hyperkalemia, particularly in patients with impaired renal function, heart failure, or those concurrently taking potassium-sparing diuretics, potassium supplements, or other agents that may increase potassium levels; therefore, serum potassium should be monitored periodically.
Dual blockade of the renin-angiotensin-aldosterone system (RAAS) with an ARB (like olmesartan), an ACE inhibitor, or aliskiren is not recommended due to an increased risk of hypotension, hyperkalemia, and renal impairment, especially in patients with diabetes.
Caution is advised in patients with severe aortic stenosis or hypertrophic obstructive cardiomyopathy, as amlodipine's vasodilatory effects could be detrimental.
Patients with impaired renal function should be closely monitored for changes in renal function and serum potassium.
The use of olmesartan in patients with severe hepatic impairment has not been adequately studied and is therefore not recommended, while amlodipine's elimination half-life is prolonged in such patients, necessitating careful titration.
In rare instances, patients with severe coronary artery disease have developed increased frequency, duration, or severity of angina or acute myocardial infarction upon initiation or dosage increase of calcium channel blockers like amlodipine.
Prescribers must evaluate these risks against the potential benefits for each individual patient.

How it Works (Mechanism of Action)

Olmesartan medoxomil and amlodipine exert their antihypertensive effects through distinct yet complementary mechanisms, leading to synergistic blood pressure reduction. Olmesartan medoxomil is a prodrug that is hydrolyzed during absorption to its active metabolite, olmesartan. Olmesartan is a selective angiotensin II type 1 (AT1) receptor antagonist. It specifically blocks the binding of angiotensin II to the AT1 receptor, which is responsible for the myriad effects of angiotensin II, including vasoconstriction, aldosterone secretion, renal sodium and water reabsorption, and sympathetic nervous system activation. By blocking these effects, olmesartan leads to peripheral vasodilation, reduced circulating blood volume, and decreased cardiac remodeling, thus lowering blood pressure. Amlodipine, on the other hand, is a dihydropyridine calcium channel blocker. It inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Amlodipine's primary action is on vascular smooth muscle, where it causes direct arterial vasodilation, leading to a reduction in peripheral vascular resistance and, consequently, a decrease in systemic blood pressure. It has minimal effect on myocardial contractility and conduction. The combination leverages these two pathways: olmesartan mitigates the effects of the renin-angiotensin-aldosterone system, while amlodipine provides direct peripheral vasodilation, resulting in a more potent and comprehensive antihypertensive action than either agent alone. This dual mechanism contributes to enhanced blood pressure control and can be particularly beneficial for patients who do not respond adequately to monotherapy.